This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.

Ano Metrogyl is a Cream used in the treatment of bedsore, hemorrhoids, fistulae and anal fissures.

Ano metrogyl is composed of Lidocaine, Metronidazole and Sucralfate.

Name of Product : ANO-metrogyl
Marketed by: J.B. Chemicals & Pharmaceuticals Ltd.
Medicine composition: Sucralfate IP (7%w/w)+ Metronidazole IP ( 1% w/w)+ Lignocaine Hydrocholoride IP ( 4% w/w) in a cream base (q.s)
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Cream
  • It is indicated for the treatment of bedsore, hemorrhoids, fistulae and anal fissures.

Route of Administration: Topical

Clean the affected area with mild soap and warm water. Rinse thoroughly and pat dry, Apply the cream with the special applicator. Cleanse the applicatory thoroughly after use. Keep the product out of Children’s reach.

ANO-metrogyl is contraindicated in patients with a history of hypersensitivity to metronidazole, amide-type local anesthetics, sucralfate or to any other ingredient in the formulation. Caution is recommended in lactating females.

ANO-metrogyl Cream should not be used during pregnancy unless considered essential by the physician. (

Download the Product Leaflet, for more details.


Avoid contact with eyes. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.

Do not apply to irritated skin or if excessive irritation develops. Dermal application may cause transient local blanching followed by transient erythema.

Download the Product Leaflet, to see the detailed warnings and precautions.

Drug interactions should be kept in mind when ANO-metrogyl cream is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical administration because of low absorption. ANO-metrogyl cream should be used with caution in patients receiving Class I anti-arrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and generally synergistic.

Download the Product Leaflet, to see the detailed drug interactions

Common (>1/100 to <1/10), Uncommon (>1/1,000 to <1/100), Rare (>1/10,000 to <1/1,000), Very rare (< 1/10,000), Not known (cannot be estimated from available data).

Skin and subcutaneous tissue disorders:
Common-Dry skin, erythema, pruritus, skin discomfort (burning, pain of skin/stinging), skin irritation, redness, itching, rash, urticaria worsening of rosacea. Unknown frequency- Contact dermatitis, swelling face, skin exfoliation.

Nervous system disorders:
Uncommon- Hypothesia, paraesthesia, dysgeusia (metallic taste).

Gastrointestinal disorders:
In rare cases local anesthetics have been associated with allergic reactions including anaphylactic shock. Corneal irritation after accidental eye exposure.

Download the Product Leafletto see the detailed information on the Undesirable Side effects/ Overdose

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties

Contact us for further information